Cure My Disease

Don't miss your cure!

 Log in / Sign up

Dual-Action antibody may boost chemoradiotherapy against High-Risk nasopharyngeal cancer

NCT ID NCT07064902

Not yet recruiting Disease control Sponsor: Sun Yat-sen University Source: ClinicalTrials.gov ↗

First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether adding ivonescimab—a drug that blocks both PD-1 and VEGF—to standard chemoradiotherapy improves outcomes for people with high-risk nasopharyngeal carcinoma. The study enrolls adults aged 18–65 with previously untreated stage T3N2M0 or stage III disease. Participants receive ivonescimab before and after chemoradiotherapy, and researchers measure how many achieve a complete response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
ivonescimab (AK112), a PD-1/VEGF bispecific antibody
What this could lead to
If successful, this combination could improve complete response rates and long-term control for high-risk nasopharyngeal carcinoma.
What could go wrong
This is an early-phase, single-arm trial with a small sample size, so results may not be definitive or generalizable. Immune-related side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CARCINOMA (NPC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

nasopharyngeal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NASOPHARYNGEAL CARCINOMA (NPC)

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Email: •••••@•••••

Locations

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, 510060, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The Affiliated Hospital of Guilin Medical University

    Guilin, Guangxi, 541001, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The First Affiliated Hospital of Xiamen University

    Xiamen, Fujian, 361003, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.